# US 12,109,345 B1 · Compositions and methods for plasmapheresis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,109,345 B1
- Document ID: US12109345B1
- Status: Granted
- Kind: B1
- Application number: 18/204,305
- Filed: 2023-05-31
- Granted: 2024-10-08
- Earliest claimed: 2022-05-31
- Assignees: Lyfspn, Inc.
- Applicants: Lyfspn, Inc.
- Inventors: Dobri Kiprov
- Web page: https://patentgrep.com/patent/US12109345B1

## CPC

- G01N 33/56972: {White blood cells}
- A61B 5/0022: {Monitoring a patient using a global network, e.g. telephone networks, internet}
- A61B 5/1118: {Determining activity level}
- A61B 5/1122: {of movement trajectories}
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61M 1/342: {Adding solutions to the blood, e.g. substitution solutions (for preventing coagulation A61M1/3672)}
- A61M 1/3496: {Plasmapheresis; Leucopheresis; Lymphopheresis (A61M1/3472 takes precedence)}
- A61M 1/36: Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation {; Extra-corporeal blood circuits}
- A61M 1/361: {before treatment}
- A61M 1/3612: {after treatment}
- A61M 1/38: Removing constituents from donor blood and {storing or} returning remainder to body {, e.g. for transfusion}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61B 5/1114: {Tracking parts of the body}
- A61M 1/362: {changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity}
- A61M 1/3693: {using separation based on different densities of components, e.g. centrifuging}
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N 2333/70578: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compositions and methods for performing plasmapheresis. The compositions and methods for performing plasmapheresis are innovative at least in their application towards the treatment and prevention of aging and conditions associated with aging. Plasmapheresis compositions and methods described herein are directed towards reducing or eliminating conditions associated with aging.

## Claims

### Claim 1

A method for using plasmapheresis to reduce cellular senescence in an individual, comprising the steps of:
(a) measuring, before an administration of the plasmapheresis, a level of expression of a marker associated with the cellular senescence in blood of the individual;
(b) administering the plasmapheresis to the individual; and
(c) measuring, following step (b), the level of expression of the marker associated with the cellular senescence and determining that the cellular senescence in the individual has been reduced.

### Claim 2 (depends on 1)

The method of claim 1, wherein a cell in which the cellular senescence is reduced comprises a lymphocyte.

### Claim 3 (depends on 2)

The method of claim 2, wherein a lymphocyte comprises a T-cell.

### Claim 4 (depends on 1)

The method of claim 1, wherein a cell in which the cellular senescence is reduced comprises a monocyte.

### Claim 5 (depends on 1)

The method of claim 1, wherein a cell in which the cellular senescence is reduced comprises a basophil.

### Claim 6 (depends on 1)

The method of claim 1, wherein a cell in which the cellular senescence is reduced comprises a neutrophil.

### Claim 7 (depends on 1)

The method of claim 1, wherein a cell in which the cellular senescence is reduced comprises an eosinophil.

### Claim 8 (depends on 1)

The method of claim 1, wherein the marker associated with the cellular senescence comprises senescence-associated beta-galactosidase (“SA-β-gal”).

### Claim 9 (depends on 1)

The method of claim 1, wherein step (a) occurs within 24 hours of the administering of the plasmapheresis to the individual in step (b).

### Claim 10 (depends on 1)

The method of claim 1, wherein the plasmapheresis that is administered in step (b) exchanges at least one unit of plasma volume.

### Claim 11 (depends on 1)

The method of claim 1, wherein the plasmapheresis that is administered in step (b) is administered over a plurality of treatment sessions.

### Claim 12 (depends on 11)

The method of claim 11, wherein two treatment sessions of the plurality of treatment sessions are administered within 72 hours of each other.

### Claim 13 (depends on 1)

The method of claim 1, wherein the plasmapheresis that is administered in step (b) is administered over a single treatment session.

### Claim 14 (depends on 1)

The method of claim 1, wherein the expression of the marker associated with the cellular senescence is measured using flow cytometry.

### Claim 15 (depends on 1)

The method of claim 1, wherein the expression of the marker associated with the cellular senescence is measured using a fluorescent conjugated antibody.

### Claim 16 (depends on 1)

The method of claim 1, wherein the reduction is a measurable decrease between level of expression of the marker associated with the cellular senescence that is measured in step (a) and the level of expression of the marker associated with the cellular senescence that is measured in step (c).

### Claim 17 (depends on 1)

The method of claim 1, further comprising repeating steps (b)-(c) until a specific value is achieved for the reduction of the level of expression of the marker associated with the cellular senescence.

### Claim 18 (depends on 1)

The method of claim 1, further comprising repeating steps (a)-(c) until a specific value is achieved for the reduction of the level of expression of the marker associated with the cellular senescence.